2014•Value in HealthOpen access

Cost-effectiveness analysis of lurasidone versus quetiapine XR in patients with bipolar depression

Ken O’Day, Mariam Hassan, Krithika Rajagopalan, Kelsey A. Meyer, Melissa Denno, Antony Loebel

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Lurasidone, Quetiapine, Quetiapine Fumarate, Bipolar disorder, Medicine, Atypical antipsychotic, Depression (economics), Bipolar I disorder